Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
27.53
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
936
Open
27.53
Bid (Size)
27.26 (1)
Ask (Size)
27.81 (1)
Prev. Close
27.53
Today's Range
27.53 - 27.53
52wk Range
22.01 - 33.71
Shares Outstanding
166,121,384
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via
Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
Performance
YTD
-3.81%
-3.81%
1 Month
-9.41%
-9.41%
3 Month
+1.81%
+1.81%
6 Month
-8.02%
-8.02%
1 Year
+3.38%
+3.38%
More News
Read More
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
March 05, 2024
Via
Chartmill
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Via
Investor's Business Daily
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Alkermes's Earnings Outlook
February 14, 2024
Via
Benzinga
Is NASDAQ:ALKS suited for growth investing?
February 07, 2024
Via
Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
January 19, 2024
Via
Chartmill
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Via
InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
Via
Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
Via
Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 12, 2024
Via
Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
February 06, 2024
Via
Investor's Business Daily
Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
January 16, 2024
Via
Chartmill
NASDAQ:ALKS, a growth stock which is not overvalued.
January 10, 2024
Via
Chartmill
Decoding 5 Analyst Evaluations For Alkermes
January 02, 2024
Via
Benzinga
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
February 02, 2024
Via
InvestorPlace
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Via
InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
February 01, 2024
Via
Chartmill
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Via
Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Via
Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in January
January 15, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.